Evidence map›Paper›PMID 39726711›Full record

ArticleFrontiers in oncology2024

Prognostic role of bone erosion in orbital RMS: a report from the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).

Daniela Di Carlo, Giulia Fichera, Veronique Minard-Colin, Beatrice Coppadoro, Daniel Orbach, Alison Cameron, Monica Albiac Ramos, Myriam Ben Arush, Johannes H M Merks, Gianni Bisogno

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Daniela Di CarloDepartment of Women's and Children's Health, University of Padova, Padova, Italy.
Giulia FicheraPediatric Radiology Unit, University Hospital of Padova, Padova, Italy.
Veronique Minard-ColinDepartment of Pediatric and Adolescent Oncology, Institut national de la santé et de la recherche médicale (INSERM) U1015, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Beatrice CoppadoroHematology Oncology Division, Department of Women's and Children's Health, University of Padova, Padova, Italy.
Daniel OrbachSoins, Innovation, Recherche, en oncologie de l'Enfant, de l'aDOlescent et de l'adulte jeune (SIREDO) Oncology Centre (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Pitié Salpêtrière (PSL) University, Institut Curie, Paris, France.
Alison CameronFRCR-Bristol Haematology and Oncology Centre, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom.
Monica Albiac RamosDepartment of Radiation Oncology, Hospital Vall d'Hebron, Barcelona, Spain.
Myriam Ben ArushJoan and Sanford Weill Pediatric Hematology Oncology and Bone Marrow Transplantation Division, Ruth Rappaport Children's Hospital, Haifa, Israel.
Johannes H M MerksPrincess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Gianni BisognoDepartment of Women's and Children's Health, University of Padova, Padova, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Orbital rhabdomyosarcoma (RMS) is often limited to the orbital cavity and has a favorable prognosis. In some cases, the tumor can erode the orbital bone and behave as a parameningeal RMS (PM-RMS); thus, it is treated more intensively. However, the current protocols do not provide any guidance on how to consider different grades of bone erosion (BE) that can vary widely, hampering a uniform classification and the subsequent treatment assignment. With the aim of clarifying the role of BE as a risk factor, we analyzed patients with orbital RMS included in the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) protocol. Methods: We retrospectively analyzed the radiological reports of 199 patients with orbital RMS (PM or not) and defined three grades of BE: minimal (thinning of the bone), moderate (focal bone lysis), and extensive (complete cortical destruction). Results: BE was present in 55 of the 199 (27.6%) patients, which was classified as minimal in 27, moderate in 7, and extensive in 21. Tumors with extensive BE were more frequently large (>5 cm, Conclusions: Only those patients with orbital RMS and extensive BE should be considered as PM and should be treated accordingly.

Indexed as

bone erosionorbital tumorparameningealpediatric rhabdomyosarcomaRMS

Identifiers

PMID39726711
PMCPMC11669659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.